Efficacy of rivastigmine on executive function in patients with parkinson's disease dementia

CNS Neuroscience and Therapeutics

Volumn 16, Issue 6, 2010, Pages 330-336

  Schmitt, Frederick A ^a   Farlow, Martin R ^b   Meng, Xiangyi ^c   Tekin, Sibel ^c   Olin, Jason T ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Executive function; Parkinson's disease dementia; Rivastigmine; Treatment

Indexed keywords

PLACEBO; RIVASTIGMINE;

AGED; ARTICLE; BRAIN CORTEX; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PLANNING; POPULATION; PROBLEM SOLVING; RANDOMIZED CONTROLLED TRIAL; THINKING; TREATMENT RESPONSE;

AGED; DEMENTIA; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PHENYLCARBAMATES; PROBLEM SOLVING; READING; THINKING; TREATMENT OUTCOME;

EID: 78649271714     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00182.x     Document Type: Article

References (22)

1. Miller EK, Cohen JD,. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 2001; 24: 167 - 202.
2. Zgaljardic DJ, Borod JC, Foldi NS, Mattis P,. A review of the cognitive and behavioral sequelae of Parkinson's disease: Relationship to frontostriatal circuitry. Cogn Behav Neurol 2003; 16: 193 - 210.
3. O'Connor MK, Boyle PA,. Executive dysfunction in Alzheimer's disease. Res Prog Alzheimer's Dis Dementia 2007; 1: 22 - 38.
4. Royall DR, Lauterbach EC, Cummings JL, et al,. Executive control function: A review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 2002; 14: 377 - 405.
5. Perry EK, Curtis M, Dick DJ, et al,. Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48: 413 - 421.
6. Farlow M, Cummings J., A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dement Geriatr Cogn Disord 2008; 25: 301 - 308.
7. Poirier J,. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002; 127:6 - 19.
8. Braak H, Rub U, Jansen Steur EN, Del Tredici K, De Vos RA,. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64: 1404 - 1410.
9. Emre M, Aarsland D, Albanese A, et al,. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509 - 2518.
10. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R,. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005; 65: 1654 - 1656. (Pubitemid 41689487)
11. Rosen WG, Mohs RC, Davis KL,. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356 - 1364.
12. Schneider LS, Olin JT, Doody RS, et al,. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl 2): S22 - S32.
13. Smith A,. Symbol digits modalities test manual. Los Angeles, CA: Western Psychological Services, 2000.
14. Delis D, Kaplan E, Kramer J,. Delis-Kaplan executive function system, San Antonio, TX: Psychological Corporation, 2001.
15. Goetz CG, Emre M, Dubois B,. Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 2008; 64 (Suppl 2): S81 - S92.
16. Janvin CC, Aarsland D, Larsen JP,. Cognitive predictors of dementia in Parkinson's disease: A community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005; 18: 149 - 154.
17. Owen AM,. Cognitive dysfunction in Parkinson's disease: The role of frontostriatal circuitry. Neuroscientist 2004; 10: 525 - 537.
18. Monchi O, Petrides M, Mejia-Constain B, Strafella AP,. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain 2007; 130: 233 - 244.
19. Zgaljardic DJ, Borod JC, Foldi NS, Mattis PJ, Gordon MF, Feigin A, Eidelberg D,. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease. J Clin Exp Neuropsychol 2006; 28: 1127 - 1144.
20. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J,. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993; 98: 431 - 438.
21. Weinstock M,. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999; 12: 307 - 323.
22. Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, Murray AD,. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2002; 13: 83 - 87.